Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 2/20 | 0.53 |
| ▸ | ESRRA | P11474 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 7/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568239 | 0.88 | PTGS1 (0.56) | ESRRBESRRAESR1ESR2PTGS1 | |
| SCHEMBL243923 | 0.88 | ESR1 (0.54) | ESRRBESRRAESR1ESR2PTGS1 | |
| SCHEMBL22536183 | 0.87 | ESR1 (0.61) | ESRRBESRRAESR1ESR2PTGS1 | |
| SCHEMBL10042949 | 0.83 | PTGS1 (0.52) | ESRRBESRRAESR1ESR2PTGS1 | |
| SCHEMBL6909272 | 0.82 | PTGS2 (0.44) | ESRRBESRRAESR1ESR2PTGS1 | |
| SCHEMBL2564011 | 0.82 | ESR1 (0.58) | ESR1ESR2PTGS1PTGS2MIF | |
| SCHEMBL8934596 | 0.82 | ESR1 (0.58) | ESR1ESR2PTGS1PTGS2MIF | |
| SCHEMBL2566862 | 0.81 | ESR2 (0.45) | ESR1ESR2PTGS1PTGS2MIF | |
| SCHEMBL2571864 | 0.81 | ESR1 (0.48) | ESRRBESRRAESR1ESR2MIF | |
| SCHEMBL2180565 | 0.80 | ESR2 (0.47) | ESR1ESR2PTGS1PTGS2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794141-B1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2011-11-09 | — | — | EP | claimed |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8084628-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084628-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESRRB 2403/4885ESRRA 2207/4885ESR1 1328/4885 |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESRRB 2403/4885ESRRA 2207/4885ESR1 1328/4885 |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESRRB 2403/4885ESRRA 2207/4885ESR1 1328/4885 |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESRRB 2403/4885ESRRA 2207/4885ESR1 1328/4885 |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESRRB 2403/4885ESRRA 2207/4885ESR1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.